Business Context and Reporting Period
This Form 8-K is a current report filed by Oculus Innovative Sciences, Inc. (not Sonoma Pharmaceuticals, Inc.) on April 26, 2007. The filing addresses corporate governance matters, specifically the adoption of a new Board Compensation Package and amendments to the 2006 Stock Incentive Plan, as well as a specific executive bonus approval.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only specific financial figures disclosed relate to compensation:
- Board Cash Compensation: $25,000 annually for non-employee directors (paid in two installments).
- Committee Stipends: Additional $5,000 for Audit Committee members, $2,000 for Compensation Committee members.
- Leadership Stipends: $15,000 for Board Chair, $10,000 for Lead Director and Audit Committee Chair, $5,000 for other Committee Chairs.
- Executive Bonus: $15,000 cash bonus paid to Mr. Bruce Thornton for performance in the year ended March 31, 2007.
Material Changes
The primary material change is the implementation of a formalized compensation structure for the Board of Directors, which previously may not have had regular cash compensation. Additionally, the 2006 Stock Incentive Plan was amended to include automatic option grants for non-employee directors, subject to stockholder approval.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, revenue outlook, or management commentary regarding business operations. The primary contingency noted is that the stock option grants for directors under the amended Stock Incentive Plan are subject to stockholder approval. No unusual items or specific risk factors were disclosed in this report.
Investor Verification Checklist
- Verify the stockholder approval status of the Amended and Restated 2006 Stock Incentive Plan.
- Confirm the total number of non-employee directors to calculate the aggregate cash and equity compensation impact.
- Review the full text of Exhibit 10.1 (Board Compensation Package) and Exhibit 10.2 (Amended Plan) for vesting schedules and forfeiture conditions.
- Check subsequent filings for the actual grant dates and exercise prices of the director stock options.